Evidence map›Paper›PMID 42196319›Full record

ArticleInternational journal of molecular sciences2026

Metabolic Endotoxemia Amplifies Estrogen Signaling Through Stromal Crosstalk in Obesity-Associated Breast Cancer.

Emmy Drai, Daniela Nahmias Blank, Esther Hermano, Adi Yifrach, Ofer Chen, Ofra Maimon, Aron Popovtzer, Tamar Peretz, Amichay Meirovitz, Michael Elkin

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emmy DraiDepartment of Oncology, Hadassah Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Daniela Nahmias BlankDepartment of Oncology, Hadassah Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Esther HermanoDepartment of Oncology, Hadassah Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Adi YifrachDepartment of Oncology, Hadassah Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Ofer ChenDepartment of Oncology, Hadassah Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.ORCID 0009-0009-5603-983X
Ofra MaimonDepartment of Oncology, Hadassah Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Aron PopovtzerDepartment of Oncology, Hadassah Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Tamar PeretzDepartment of Oncology, Hadassah Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Amichay MeirovitzLegacy Heritage Oncology Center and Dr. Larry Norton Institute, Soroka University Medical Center, Be'er Sheva 84101, Israel.ORCID 0000-0001-7479-2926
Michael ElkinDepartment of Oncology, Hadassah Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.

Funding

Israel Science Foundation 2292/21
6 · The paper itself

Abstract

Obesity has been consistently associated with several types of malignant tumors, including hormone-responsive breast carcinoma (BC) in postmenopausal patients. BC is the most diagnosed malignancy and the leading cause of cancer-related morbidity and mortality among women worldwide. The predominant association between obesity and hormone-responsive BC subtypes is often explained by the increased local production of estrogens due to upregulation of aromatase, the rate-limiting enzyme in estrogen biosynthesis, in the chronically inflamed "obese" adipose tissue. However, the underlying molecular mechanisms are not fully defined. One potential mediator of inflammatory responses in the setting of obesity is bacterial endotoxin. Indeed, subclinical concentrations of endotoxin are chronically present in the circulation of obese patients and experimental animals (the phenomenon termed 'metabolic endotoxemia' [ME]). Here, we investigated whether ME conditions are mechanistically involved in augmented estrogen reactivity that sustains the obesity-BC link, focusing primarily on ME effects on key cellular components of the BC microenvironment (i.e., fibroblasts, macrophages). Our findings identify ME as a microenvironmental driver that directly induces aromatase expression in adipose fibroblasts, and simultaneously triggers upregulation of estrogen receptor levels in breast tumor cells via a macrophage-mediated mechanism. This dual action of ME in fueling obesity-accelerated hormone-dependent breast tumorigenesis may suggest new avenues for both therapeutic intervention and prevention of BC-promoting consequences of excess adiposity in an increasingly obese population.

Indexed as

Breast NeoplasmsEndotoxemiaEstrogensObesitySignal TransductionAdipose TissueAnimalsAromataseCell Line, TumorFemaleFibroblastsHumansMacrophagesReceptors, EstrogenTumor MicroenvironmentAromataseEstrogensReceptors, Estrogenbreast carcinomaestrogenfibroblastsmacrophagesobesity

Identifiers

PMID42196319
PMCPMC13207763

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.